BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label, Phase 2/3 study that will evaluate the
efficacy and safety of bempegaldesleukin (BEMPEG; NKTR-214) combined with pembrolizumab
compared with pembrolizumab monotherapy in patients with recurrent or metastatic HNSCC with
positive PD-L1 expression (CPS ≥ 1).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nektar Therapeutics
Collaborators:
Merck Sharp & Dohme Corp. SFJ Pharmaceuticals, Inc.